A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT03797391

Public ClinicalTrials.gov record NCT03797391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

Study identification

NCT ID: NCT03797391
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.; Industry
Enrollment: 186 participants

Conditions and interventions

Conditions

Interventions

EMB-01 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 12, 2018
Primary completion: Mar 13, 2025
Completion: Jan 14, 2026
Last update posted: May 30, 2023

2018 – 2026

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Gabrail Cancer Center Research	Canton	Ohio	44718	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03797391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 30, 2023 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03797391 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →